LabShares Newton Selects Two Startups ? Interon Labs and Proteinea, as Winners of Third Launch@LabShares Pitch Competition

LabShares Newton, a shared office and laboratory incubator for emerging life science companies, announced today that it has selected two companies as winners of the 2022 Launch@LabShares Pitch Competition. Launch@LabShares began in 2018 as an effort to help support early stage, exciting startups with a clear, solid plan for their research, growth and path to positive patient outcomes.

Both winners, Interon Labs and Proteinea, will receive a free benches in LabShares' fully equipped BL2 space for one year. The prize also includes office space, full access to all LabShares' services and amenities, and use of state-of-the-art equipment. Launch@LabShares is generously sponsored by DT Ward PC, Faber Daeufer & Itrato, ThermoFisher Scientific, Tobin Scientific, and Safety Partners, Inc.

"We are thrilled to award free lab space to these two exciting startups," said Jeff Behrens, LabShares CEO, "Our mission is to support the biotech entrepreneurial ecosystem and both Interon and Proteinea are great examples working on challenging and important problems in neuro-immunology and protein discovery/optimization."

Interon Labs, already a LabShares resident, is seeking to expand their footprint in 2023. Interon is pioneering immunotherapy for the brain and is developing treatments for neurological disorders, beginning with autism. Interon's revolutionary science includes discoveries made by Interon's Co-Founders at MIT and Harvard Medical School, and was featured in journals including Nature, Science and Cell.

"LabShares has been a tremendous ally in advancing Interon's scientific and business progress," said Paul Singh, Interon Laboratories' CEO. "Labshares and Interon both share a common goal of solving complex human health problems and we look forward to expanding our partnership together."

The second winner, Proteinea, was founded in Egypt and aims to offer the next generation of full-stack biomanufacturing technologies to make protein therapeutics more accessible through innovative design and production methods. Proteinea uses its proprietary computational platform and protein language models to solve inherent, hard-to-solve problems in antibody design with a focus on Fc optimization/modification and the ability to design new modalities faster and more effectively.

"We are very excited about our expansion to Boston through LabShares," shared Mahmoud Eljendy, founder and CEO of Proteinia. "The company was born out of Egypt and is now expanding to Boston to enable more antibody and cell therapy developers to have better modalities efficiently using our powerful computational platform."

About LabShares Newton
LabShares Newton is an office and BL2 laboratory incubator for emerging biotechnology and life science start-ups, offering options for shared lab space or private lab suites. LabShares goal is to provide best in class service, facilities and equipment to startups of all sizes and stages. For more information on LabShares, or to arrange a tour, please contact [email protected].